Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-12-15
2008-08-19
Wilson, James O. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S241000, C548S361100
Reexamination Certificate
active
07414132
ABSTRACT:
A compound of the formula (I); wherein the variables X1to X10, R1to R7including R3′, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
REFERENCES:
patent: WO 98/09625 (1998-03-01), None
patent: WO 00/40560 (2000-07-01), None
patent: WO 02/38544 (2002-05-01), None
patent: WO 02/078693 (2002-10-01), None
patent: WO 2004/026305 (2004-04-01), None
patent: WO 2004/080968 (2004-09-01), None
patent: WO 2004/080996 (2004-09-01), None
Patani and LaVoie. Chemical Reviews, 1996, 96, 3147-76.
Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Daintith, J. A Dictionary of Chemistry, 1996, pags 157 and 353-54.
De La Torre Marta Garcia
Diaz Buezo Nuria
Jadhav Prabhakar Kondaji
Mitch Charles Howard
Pedregal-Tercero Concepcion
Demeter John C.
Eli Lilly and Company
Ginah Francis O.
Jarrell Noble
Wilson James O.
LandOfFree
Opioid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opioid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opioid receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3998674